EGFR and neoplasm: Whereas microsatellite instability has recently emerged as a positive biomarker for the selection of mCRC patients who benefit from immunotherapeutic agents, such as pembrolizumab and nivolumab [64,65,66], preliminary data put it on the horizon of molecular markers with a supposed impact on tumor sensitivity to EGFR inhibition.